Mukund Paravasthu
CIK: 0002039078
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NovoCure Ltd
Discretionary Trading P&L
Holdings
Transaction History (18 total)
- Mar 5, 2026NVCR
NovoCure Ltd
Sale(S)Direct43.2K shares at avg. $13.77$596K - Mar 4, 2026NVCR
NovoCure Ltd
Sale(S)Direct5.4K shares at avg. $13.31$72K - Mar 3, 2026NVCR
NovoCure Ltd
Award(A)Direct45.1K shares- - Mar 2, 2026NVCR
NovoCure Ltd
Sale(S)Direct408 shares at avg. $13.49$6K - Feb 27, 2026NVCR
NovoCure Ltd
Sale(S)Direct1.6K shares at avg. $13.66$21K - Jan 11, 2026NVCR
NovoCure Ltd
Tax Payment(F)Direct2.1K shares at avg. $14.35$31K - Nov 4, 2025NVCR
NovoCure Ltd
Tax Payment(F)Direct2.9K shares at avg. $12.23$36K - Nov 1, 2025NVCR
NovoCure Ltd
Tax Payment(F)Direct168 shares at avg. $12.81$2K - May 3, 2025NVCR
NovoCure Ltd
Sale(S)Direct592 shares at avg. $17.91$11K - Mar 4, 2025NVCR
NovoCure Ltd
Award(A)Direct55K shares at avg. $18.19$1000K - Mar 3, 2025NVCR
NovoCure Ltd
Sale(S)Direct250 shares at avg. $18.54$5K - Feb 28, 2025NVCR
NovoCure Ltd
Sale(S)Direct368 shares at avg. $18.28$7K - Feb 27, 2025NVCR
NovoCure Ltd
Sale(S)Direct1.4K shares at avg. $19.92$27K - Feb 27, 2025NVCR
NovoCure Ltd
Sale(S)Direct267 shares at avg. $20.55$5K - Jan 11, 2025NVCR
NovoCure Ltd
Sale(S)Direct2.2K shares at avg. $26.81$58K - Nov 4, 2024NVCR
NovoCure Ltd
Award(A)Direct30.1K shares- - Nov 2, 2024NVCR
NovoCure Ltd
Sale(S)Direct44 shares at avg. $16.69$734.175 - Nov 1, 2024NVCR
NovoCure Ltd
Sale(S)Direct160 shares at avg. $15.88$3K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 5, 2026 | NVCR NovoCure Ltd | Sale(S) | 43,246 | $13.77 | $595,670 | Direct |
| Mar 4, 2026 | NVCR NovoCure Ltd | Sale(S) | 5,377 | $13.31 | $71,543 | Direct |
| Mar 3, 2026 | NVCR NovoCure Ltd | Award(A) | 45,112 | - | $0 | Direct |
| Mar 2, 2026 | NVCR NovoCure Ltd | Sale(S) | 408 | $13.49 | $5,505 | Direct |
| Feb 27, 2026 | NVCR NovoCure Ltd | Sale(S) | 1,555 | $13.66 | $21,247 | Direct |
| Jan 11, 2026 | NVCR NovoCure Ltd | Tax Payment(F) | 2,133 | $14.35 | $30,609 | Direct |
| Nov 4, 2025 | NVCR NovoCure Ltd | Tax Payment(F) | 2,949 | $12.23 | $36,066 | Direct |
| Nov 1, 2025 | NVCR NovoCure Ltd | Tax Payment(F) | 168 | $12.81 | $2,152 | Direct |
| May 3, 2025 | NVCR NovoCure Ltd | Sale(S) | 592 | $17.91 | $10,604 | Direct |
| Mar 4, 2025 | NVCR NovoCure Ltd | Award(A) | 54,975 | $18.19 | $999,995 | Direct |
| Mar 3, 2025 | NVCR NovoCure Ltd | Sale(S) | 250 | $18.54 | $4,634 | Direct |
| Feb 28, 2025 | NVCR NovoCure Ltd | Sale(S) | 368 | $18.28 | $6,729 | Direct |
| Feb 27, 2025 | NVCR NovoCure Ltd | Sale(S) | 1,379 | $19.92 | $27,472 | Direct |
| Feb 27, 2025 | NVCR NovoCure Ltd | Sale(S) | 267 | $20.55 | $5,487 | Direct |
| Jan 11, 2025 | NVCR NovoCure Ltd | Sale(S) | 2,160 | $26.81 | $57,906 | Direct |
| Nov 4, 2024 | NVCR NovoCure Ltd | Award(A) | 30,138 | - | $0 | Direct |
| Nov 2, 2024 | NVCR NovoCure Ltd | Sale(S) | 44 | $16.69 | $734 | Direct |
| Nov 1, 2024 | NVCR NovoCure Ltd | Sale(S) | 160 | $15.88 | $2,540 | Direct |
1-18 of 18 transactions
About Paravasthu Mukund
Paravasthu Mukund (SEC CIK 0002039078) files insider reports with the SEC as Chief Operating Officer of NovoCure Ltd (NVCR).
Signal8 holds 13 ownership filings by Paravasthu Mukund (1 Form 3, 12 Form 4), filed between Oct 9, 2024 and Mar 5, 2026. Those filings report 18 transactions, from Nov 1, 2024 to Mar 5, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Paravasthu Mukund's filings is in WAYNE, PA.
Recent filings by Paravasthu Mukund
- Mar 5, 2026: Open-market sale of NVCR shares (Form 4, code S).
- Mar 4, 2026: Open-market sale of NVCR shares (Form 4, code S).
- Mar 3, 2026: Grant or award of NVCR shares (Form 4, code A).
- Mar 2, 2026: Open-market sale of NVCR shares (Form 4, code S).
- Feb 27, 2026: Open-market sale of NVCR shares (Form 4, code S).
Other insiders filing for NovoCure Ltd (NVCR)
- Puri Michal Nath, Chief Human Resources Officer
- Leonard Frank X, Chief Executive Officer
- Ben Arye Barak, General Counsel
- Danziger Asaf, Director
- LEUNG GABRIEL, Director
- Stafford Kristin, Director